The Burzynski Clinic (BC) announced today that it made a keynote speaker
presentation at the 2nd Annual Congress of Asia-Pacific
Academy of Anti-Aging Medicine in Beijing, China. Based on the
presentation in Beijing, a total of 401 eligible patients (patients who
received over 28 days of treatment) with advanced inoperable brain
tumors have been treated with antineoplaston A10 and antineoplastons
AS2-1 therapy (ANP) in phase II studies. Most of the patients (87%) were
diagnosed with high-grade tumors and the remaining patients were
diagnosed with low-grade tumors. The patients were diagnosed by
pathologists not associated with BC and objective responses were
verified by Central Radiology Review. The group of 77 patients (19%)
survived over five years from the treatment start. Of particular
interest were results in patients with brainstem gliomas. The group of
17 patients with brainstem glioma underwent the treatment and 65% of
these patients survived over five years. An additional group of 42
patients diagnosed with diffuse intrinsic pontine glioma (DIPG) have
been treated and a total of 19% survived over five years.
The quality of survival is very good and there is no long-term toxicity
related to ANP.
These clinical results are very encouraging, since they describe a
positive ANP effect on some of the worst malignancies in the entire
oncology field, but they will require FDA approval.
Burzynski Clinic is committed to developing treatments for cancer based
on genomic and epigenomic principles.
Forward-looking statements in this release are made pursuant to the
safe harbor provisions of the federal securities laws. Information
contained in forward-looking statements is based on current expectations
and is subject to change, and future events may differ materially from
those discussed herein due to a number of factors, including, but not
limited to, risks and uncertainties related to the clinic's ability to
use Antineoplastons A10 and AS2-1. Burzynski Clinic does not
undertake to update any such forward-looking statements or to publicly
announce developments or events relating to the matters described herein.
For Burzynski Clinic
Carolyn Powers, 713-335-5664